Webster Bank N. A. reduced its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) by 44.6% during the first quarter, Holdings Channel.com reports. The fund owned 1,825 shares of the company’s stock after selling 1,470 shares during the quarter. Webster Bank N. A.’s holdings in Invesco Biotechnology & Genome ETF were worth $118,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of PBE. One Capital Management LLC purchased a new position in Invesco Biotechnology & Genome ETF in the fourth quarter worth $1,304,000. Creative Financial Designs Inc. ADV raised its position in Invesco Biotechnology & Genome ETF by 6.6% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 3,347 shares of the company’s stock valued at $220,000 after purchasing an additional 206 shares in the last quarter. YHB Investment Advisors Inc. raised its position in Invesco Biotechnology & Genome ETF by 0.9% during the fourth quarter. YHB Investment Advisors Inc. now owns 22,755 shares of the company’s stock valued at $1,498,000 after purchasing an additional 200 shares in the last quarter. Kestra Advisory Services LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 4.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 6,362 shares of the company’s stock valued at $363,000 after buying an additional 254 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new stake in Invesco Biotechnology & Genome ETF in the 4th quarter worth approximately $39,000.
Invesco Biotechnology & Genome ETF Price Performance
Shares of NYSEARCA PBE opened at $64.81 on Friday. The stock has a market capitalization of $261.85 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a one year low of $52.47 and a one year high of $67.76. The firm’s 50 day simple moving average is $63.71 and its two-hundred day simple moving average is $64.30.
Invesco Biotechnology & Genome ETF Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.
Recommended Stories
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- The Significance of Brokerage Rankings in Stock Selection
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 6/24 – 6/28
- What Makes a Stock a Good Dividend Stock?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report).
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.